Article

Enhanced T Cell Lymphoma in NOD.Stat5b Transgenic Mice Is Caused by Hyperactivation of Stat5b in CD8 Thymocytes

Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, Augusta, Georgia, United States of America
PLoS ONE (Impact Factor: 3.23). 02/2013; 8(2):e56600. DOI: 10.1371/journal.pone.0056600
Source: PubMed

ABSTRACT

Activation of signal transducers and activators of transcription (STAT) proteins may be critical to their oncogenic functions as demonstrated by the development of B-cell lymphoma/leukemia in transgenic (TG) mice overexpressing a constitutively activated form of Stat5b. However, low incidence of CD8 T cell lymphoma was observed in B6 transgenic mice overexpressing a wild-type Stat5b (B6.Stat5b) despite of undetectable Stat5b phosphorylation and the rate of lymphomagenesis was markedly enhanced by immunization or the introduction of TCR transgenes [1]. Here, we report that the wild-type Stat5b transgene leads to the acceleration and high incidence (74%) of CD8 T cell lymphoblastic lymphomas in the non-obese-diabetic (NOD) background. In contrast to the B6.Stat5b mice, Stat5b in transgenic NOD (NOD.Stat5b) mice is selectively and progressively phosphorylated in CD8 thymocytes. Stat5 phosphorylation also leads to up-regulation of many genes putatively relevant to tumorigenesis. Treatment of NOD.Stat5b mice with cancer chemopreventive agents Apigenin and Xanthohumol efficiently blocked lymphomagenesis through reduction of Stat5 phosphorylation and genes up-regulated in the NOD.Stat5b mice. These results suggest that NOD genetic background is critical to the Stat5b-mediated lymphomagenesis through regulation of Stat5 hyperactivation. NOD.Stat5b mouse is an excellent model for studying the molecular mechanisms underlying lymphomagenesis and testing novel chemoprevention strategies.

Download full-text

Full-text

Available from: Ashok Sharma
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myeloid leukemia (CML) is a hematological stem cell disorder characterized by the excessive proliferation of the myeloid lineage. In its initial chronic phase, the myeloid progenitor cells expand and demonstrate apparently normal differentiation. The disease may then transform into the accelerated phase, usually associated with resistance to therapy, and finally, into acute leukemic progression phase - blast crisis. Abnormal myeloid cells produce progenitors, which have lost their ability to differentiate, but retain the capacity to proliferate. The molecular hallmark of CML is the Philadelphia chromosome, resulting from reciprocal chromosome translocation, t(9;22)(q34;q11), and containing the BCR/ABL fusion gene, producing the BCR/ABL protein with a constitutive tyrosine kinase activity. BCR/ABL-positive cells have faster growth and proliferation over their normal counterparts and are resistant to apoptosis. Introduction of imatinib (IM), a tyrosine kinase inhibitor, revolutionized the therapy of CML, changing it from a fatal disease into a chronic disorder. However, some patients show a primary resistance to IM, others acquire such resistance in the course of therapy. Therefore, a small number of leukemic stem cells retains self-renewal capacity under IM treatment. Because BCR/ABL is involved in many signaling pathways, some of them may be essential for resistance to IM-induced apoptosis. The PI3K/AKT, Ras and JAK/STAT signaling pathways are involved in resistance to apoptosis and can be activated by BCR/ABL. Therefore, they can be candidates for BCR/ABL-dependent pro-survival pathway(s), allowing a fraction of CML cells to withstand treatment with tyrosine kinase inhibitors.
    No preview · Article · Nov 2013 · Acta biochimica Polonica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Contact Hypersensitivity Assay (CHS) faithfully models human allergies. The Stat5 transcription factors are essential both for lymphocytes development and acute immune responses. Although consequences of Stat5 ablation and transgenic over expression for the lymphocytes development and functions have been extensively studied, the role of Stat5 gene dosage in contact allergies have not been addressed.Objective We investigated effect of Stat5 gene dosage modulation in contact allergies using CHS in mice.Methods Transgenic animals heterozygous for the germline Stat5 null allele were subjected to CHS assay. To dissect cell type sensitive to Stat5 gene dosage, animals with Stat5 haplo-insufficiency in T cells, where one Stat5 allele was removed by Lck-Cre- mediated deletion (Stat5ΔT/+), were tested by CHS assay. Frequency of T -, B- cells and monocytes were analyzed in Stat5ΔT/+ and wild type animals by flow cytometry. Proliferation of Stat5ΔT/+ CD8+ T cells were studied in vitro by stimulation with IL-4 and IL-2 cytokines and changes in expression of Stat5 target genes were assayed by quantitative real time PCR assay.ResultHaplo-insufficiency of Stat5 in T cells leads to reduction of CD8+ T cells in all lymphoid organs and attenuates CHS response. Stat5ΔT/+ CD8+ T cells failed to fully activate Stat5 dependent expression of cell cycle/survival target genes, such as bcl-2 and pim1, and to proliferate efficiently in response to IL-2 and IL-4 cytokine.Conclusion: Our data identify Stat5 as a dose dependent regulator of CD8+ T cell functions in contact allergies and suggest that modulation of Stat5 dosage could be used to target contact allergies in humans.This article is protected by copyright. All rights reserved.
    No preview · Article · Oct 2014 · Allergy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Isoxanthohumol (IXN), a prenylated flavonoid from hops, exhibits diverse biological activities, e.g. antitumor, antiinflammatory, antioxidant and antiangiogenic. In this study, the effect of IXN is evaluated on two melanoma cell lines with dissimilar molecular background, B16 and A375. The treatment of both cell lines with IXN resulted in dose-dependent decrease of cell viability. Abolished viability was in correlation with changed morphology and loss of dividing potential indicating phenotypical alteration of both tested cell lines. While modified B16 cells underwent the process of non-classic differentiation followed by tyrosinase activity without enhancement of melanin content, inhibition of Notch 1, β-catenin and Oct-3/4 were observed in A375 cells indicating loss of their pluripotent characteristics. In parallel with this, distinct subpopulations in both cell cultures entered the process of programmed cell death - apoptosis in a caspase independent manner. The described changes in cultures upon exposure to IXN could be connected with the suppression of reactive oxygen (ROS) and nitrogen species (RNS) induced by the drug. Despite the differences in which IXN promoted modifications in the upper part of the PI3K/Akt and MEK-ERK signaling pathways between B16 and A375 cells, p70S6K and its target S6 protein in both types of melanoma cells, after transient activation, became inhibited. In addition to direct input of IXN on cell viability, this study for the first time shows that IXN strongly sensitizes melanoma cells to the treatment with paclitaxel in vivo, in concordance with data obtained in vitro on B16 cells as well as their highly invasive F10 subclone.
    No preview · Article · Jan 2016 · Pharmacological Research